Evidence map›Paper›PMID 32213336›Full record

ArticleThe Lancet. Infectious diseases2020

SARS-CoV-2: virus dynamics and host response.

Yu Chen, Lanjuan Li

2 registry-linked trialsAbstract readComment
In one paragraph

Article in The Lancet. Infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 140 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
140citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04632537 phase3withdrawnnot on this map

Novel Use of an Existing Vaccine (BCG) Alliance: The NUEVA Trial

TypeinterventionalSponsorHenry M. Jackson Foundation for the Advancement of Military MedicineRan2020 to 2021Enrolled0ConditionsCOVID-19ArmsTice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine, Preservative-free saline
NCT04938323 phase2 / phase3withdrawnnot on this mapstarted 2022, after this paper: background citation

Prevention of Acute Respiratory Infection in Taiwanese Institutionalized Elderly (PARITIE)

TypeinterventionalSponsorHarvard Medical School (HMS and HSDM)Ran2022 to 2022Enrolled0ConditionsAcute Respiratory InfectionArmsBCG Vaccine, Placebo
3 · Its place in the literature

Who cites it

140 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Journal of public health in Africa · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Pharmacological potential ofFrontiers in immunology · 2023
    Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

80 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Yu ChenState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Centre for Infectious Diseases, Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
Lanjuan LiState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Centre for Infectious Diseases, Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China. Electronic address: ljli@zju.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Severe acute respiratory syndrome-related coronavirusAntibody FormationBetacoronavirusCohort StudiesCoronavirus InfectionsCOVID-19PandemicsPneumonia, ViralSalivaSARS-CoV-2Viral Load

Identifiers

PMID32213336
PMCPMC7156233

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.